
(1) University of Nottingham, Nottingham, UK; University Hospitals of Derby and Burton, United Kingdom;(2) LTD Brothers, Batumi, Georgia;(3) Acad. Fridon Todua Medical Center;(4) Instituto Nacional de Cancerologa (INCAN), Mexico City, Mexico;(5) Helscore Israeli Gergian Medical Research Clinic, Georgia;(6) Injury, Recovery and Inflammation Sciences, University of Nottingham, United Kingdom;(7) School of Medicine, University of Nottingham, Royal Derby Hospital Centre, United Kingdom;(8) The Institute of Clinical Oncology, Georgia;(9) Astra Zeneca;(10) AstraZeneca, United Kingdom;(11) Research and Early Development, Oncology R&D, AstraZeneca, United Kingdom;(12) LTD S. Khechinashvili University Hospital, Georgia.

RF01-02 **A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: evaluation of dermal safety, intra-mammary drug distribution, and biologic effects.** Oukseub Lee (1) Latifa Bazzi (2) Yanfei Xu (2) Erik Pearson (2) Minhua Wang (2) Omid Hosseini (2) Azza Akasha (2) Jennifer Choi (2) Masha Kocherginsky (2) Kelly Benante (3) Thomas Helland (4) Gunnar Mellgren (4) Eileen Dimond (5) Marjorie Perloff (6) Brandy Heckman-Stoddard (7) Seema Khan (1) Scott Karlan (8) Melissa Pilewskie (9)

(1) Northwestern University, Chicago, Illinois, United States;(2) Northwestern University;(3) Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States;(4) Haukeland University Hospital, Norway;(5) National Cancer Institute, DCP, MD, United States;(6) National Cancer Institute Division of Cancer Prevention;(7) National Cancer Institute;(8) Cedars-Sinai Medical Center;(9) University of Michigan, Ann Arbor, MI, United States.


(1) 17 Medical Oncology Department, Hospital Arnau de Vilanova, Spain;(2) International Breast Cancer Center (IBCC), Pangea Oncology, Quiron Group, Barcelona, Spain; Medica Scienitca Innovation Research (MEDISt), Barcelona, Spain and Ridgewood, New Jersey, US., Catalonia, Spain;(3) Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Spain;(4) Oncopole Claudius-Regaud, IUCT, France;(5) Institut Català d’Oncologia, Insitut d’Investigació Biomèdica Bellvitge. GEICAM Spanish Breast Cancer Group;(6) Hospital Universitario Virgen del Rocio, Sevilla, Andalucia, Spain;(7) Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain; SOLTII Cancer Research Group;(8) Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, United Kingdom;(9) Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain;(10) Royal Cornwalll Hospitals NHS Trust, Truro, England, United

(1) The University of Texas MD Anderson Cancer Center, Houston, TX, United States;(2) Faculté de Medicine Paris-Sud XI, Gustave Roussy, France;(3) University of Texas Southwestern Medical Center, Dallas, TX, United States;(4) Instituto Português de Oncologia do Porto FG, Portugal;(5) Mayo Clinic, Rochester, MN, United States;(6) Duke University Medical Center, University of Tennessee Health Science Center College of Medicine, Chattanooga, TN, United States;(7) Division of Medical Genomics, IEO, European Institute of Oncology, IRCCS, Milan, Lombardia, Italy;(8) Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal;(9) Medical Oncology, Centre Léon Bérard, France;(10) Christie Hospital NHS Foundation Trust, University of Manchester, United Kingdom;(11) Florida Cancer Specialists, New Port Richey, FL, United States;(12) Taiho Oncology, Inc., Princeton, NJ, United States;(13) Royal Marsden Hospital, Institute of Cancer Research, London, England, United Kingdom.

RF01-05 Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer. Elizabeth Harvey-Jones (1) Maya Raghunandan (2) Luisa Robbez-Masson (2) Thanussuyah Alaguthurai (3) Alba Llop-Guevara (4) Jennifer Trendell (3) Olga Rodriguez (4) Marta Guzman (4) Daniel Weekes (2) Christelle deRenty (5) Eleanor Knight (2) Rebecca Marlow (2) Christopher Starling (2) Ruifang Liu (3) Nivedita Ravindran (2) Ioannis Roxanis (6) Natalia Lukashchuk (5) Violeta Serra (4) Stephen Pettitt (2) Christopher Lord (2) Andrew NJ Tutt (7)

(1) King’s College London, Great Maze Pond, England, United Kingdom;(2) Institute of Cancer Research;(3) King’s College London;(4) Val D’Hebron Institut D’Oncologia;(5) Astra Zeneca;(6) The Institute of Cancer Research;(7) Institute of Cancer Research, King’s College London and Guy’s Cancer Centre.

RF01-06 Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer: a multicenter phase II trial based on a Bayesian adaptive randomized design. Hongnan Mo (1) Xiaoying Sun (2) Jingtong Zhai (3) Jiashu Han (3) Hewei Ge (3) Yuhan Wei (3) Xiwen Guan (3) Haiili Qian (3) Fei Ma (4)
RF01-07 The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC. Piha-Paul Sarina (1) Binghe Xu (2) Ying Fan (2) Yuan Yuan (3) Sayeh Lavasani (4) Joanne Mortimer (5) Sanjay Goel (6) Apostolia Tsimberidou (1) Nuhad Ibrahim (1) Sausan Abouharb (1) Carlos Barcenas (1) Adaeze Iheme (1) Daniel Karp (1) Jordi Rodon Ahnert (1) Ecaterina Dumbrava (1) Jean Fan (7) Peng Peng (8) Caixia Sun (8) Hui Wang (8) Katie Hennessy (7) Ximei Fu (8) Ruolan Xu (8) Shumao Ni (8) Frank Wu (8) Funda Meric-Bernstam (1) (1) The University of Texas MD Anderson Cancer Center, Houston, TX, United States; (2) Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China; (3) Cedars-Sinai Cancer; (4) UCI Health; (5) City of Hope, Duarte, California, United States; (6) Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States; (7) TransThera Sciences (US), Inc.; (8) TransThera Sciences (Nanjing), Inc., China (People's Republic).

RF01-08 A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy-induced Nausea and vomiting in solid tumors (OLAnzapINE). Jyoti Bajpai (1) Venkatesh Kapu (1) Sushmita Rath (1) Sravan Kumar (2) Anbarasan Sekar (2) Srikanth Anne (2) Akash Pawar (2) Sujay Srinivas (3) Prabhat Bhargava (2) Seema Gulia (2) Rajiv Sarin (4) Rajendra Badwe (5) Sudeep Gupta (2) (1) Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India; (2) Tata Memorial Centre, Homi Bhabha National Institute (HBNI); (3) Tata memorial hospital; (4) Tata Memorial Hospital; (5) Tata Memorial Centre, India.
RF02-01 A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab in Hormone Receptor (HR)-Positive, HER2-Positive Metastatic Breast Cancer (ASPIRE). Rima Patel (1) Krystal Cascetta (1) Paula Klein (1) Erin Moshier (2) Maryann Kwa (3) Julie Fasano (1) Anupama Goel (4) Melissa Accordino (5) Charles Shapiro (6) Rita Vaccaro (7) Gargi Atul Joshi (8) Joseph Sparano (9) Amy Tiersten (10) (1) Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute; (2) Icahn School of Medicine at Mount Sinai; (3) New York University; (4) Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute; (5) Columbia University Medical Center; (6) Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute; (7) Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai; (8) University of Vermont Cancer Center; (9) Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, United States; (10) Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New, New York, United States.

RF02-02 BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism. Pedro Beltran (1) Simanshu Dhirendra (2) Rui Xu (3) Ming Chen (3) Daniel Czyzynk (4) Sofia Donovan (3) Siyu Feng (3) Cindy Feng (3) Liujuan Fu (3) Felice Lightstone (5) Ken Lin (3) Anna Maciag (4) Dwight Nissley (4) Erin Riegler (3) Kerstin Sinkevicius (3) Andrew Stephen (4) James Stice (3) David Turner (4) Bin Wang (3) Keshi Wang (3) Yue Yang (5) Cathy Zhang (3) Frank McCormick (6) Eli Wallace (3) (1) BridgeBio Pharma Oncology Therapeutics, Orinda, California, United States; (2) NCI RAS Initiative, Frederick National Laboratory for Cancer Research; (3) BridgeBio Pharma Oncology Therapeutics; (4) Frederick National Laboratory for Cancer Research; (5) Lawrence Livermore National Laboratory; (6) UCSF.

RF02-03 Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08). Komal Jhaveri (1) Fabrice André (2) Erika Hamilton (3) Peter Schmid (4) Carey Anders (5) Laura Testa (6) Inna Ganshina (7) Yen-Shen Lu (8) Seock-Ah Im (9) Robyn Young (10) Magdalena Wrona (11) Caron Lloyd (12) Yiwen Zhang (13) Sherene Loi (14) (1) Memorial Sloan Kettering Cancer Center, New York, NY, United States; (2) Faculté de Medicine Paris-Sud XI, Gustave Roussy, France; (3) Sarah Cannon Research Institute (SCRI), Nashville, TN, United States; (4) Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, United Kingdom; (5) Duke Cancer Institute, Durham, NC, United States; (6) Instituto D’Or de Pesquisa e Ensino (IDOR), Brazil; (7) N.N. Blokhin National Medical Research Center of Oncology, Russia; (8) National Taiwan University Hospital; Taiwan; (9) Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea; (10) The Center for Cancer and Blood Disorders, TX, United States; (11) Enhertu, Late Development Oncology, Global Medicines Development, Late Oncology R&D, AstraZeneca, Warsaw, Mazowieckie, Poland; (12) Enhertu, Late Development Oncology, Global Medicines Development, Late Oncology R&D, AstraZeneca, New York, NY, United States; (13) Late Oncology Statistics, Statistics, Late Oncology R&D, AstraZeneca, Gaithersburg, MD, United States; (14) Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

RF02-04 A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with metastatic HER2-positive breast cancer. (JCOG1607 HERB TEA study). Akihiko Shimomura (1) Kenji Tamura (2) Keita Sasaki (3) Ryo Sadate (4) Akihiko Suto (5) Masataka
RF02-05 Report on Cohort Expansion of Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with Locally Advanced/Metastatic HER2 Low Breast Cancer. Fei Ma (1) Pamela Munster (2) Xiaoxiang Guan (3) Jingfen Wang (4) Herui Yao (5) Erika Hamilton (6) Xian Wang (7) Yehui Shi (8) Xinzun Liang (9) Nong Xu (10) Huoling Tang (11) Yuhong Zhou (11) Ziping Wei (11) (1) Cancer Hospital, Chinese Academy of Medical Sciences, China; (2) University of California San Francisco, San Francisco, CA, United States; (3) Jiangsu Province Hospital; (4) Linyi Cancer Hospital; (5) Sun Yat-sen Memorial Hospital, Sun Yat-sen University; (6) Sarah Cannon Research Institute (SCRI), Nashville, TN, United States; (7) Sir Run Run Shaw Hospital; (8) Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy; (9) Hubei Cancer Hospital, China; (10) The First Affiliated Hospital, Zhejiang University, School of Medicine; (11) Bliss Biopharmaceutical (Hangzhou) Co., Ltd.

RF02-06 AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658). Adrienne Waks (1) Ruichao Shi (2) Meredith Regan (1) Chau Dang (3) Cesar Santa-Maria (4) Kelly Westbrook (5) Vandana Abramson (6) Rashmi Murthy (7) Rita Nanda (8) Hope Rugo (9) Amy Clark (10) Candace Mainor (11) Claire Dees (12) Valentina Hoyos (13) Kathy Miller (14) Erica Stringer-Reaor (15) Natasha Hunter (16) Sun Young Oh (17) Michelle DeMeo (1) Amanda Okpoeb (2) Erin Elias (2) Busem Kurt (18) Nancy Lin (19) Mithaffar Rimawi (20) Antonio Wolff (21) Elizabeth Mittendorf (22) Shom Goel (23) Sara Tolancy (1) Sherene Loi (24) Ian Krop (25) (1) Dana-Farber Cancer Institute, Boston, MA, United States; (2) Dana-Farber Cancer Institute; (3) Breast Medicine Service, Memorial Sloan-Kettering Cancer Center; (4) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Baltimore, MD & Sibley Memorial Hospital, Johns Hopkins, Washington, DC, Baltimore, MD, United States; (5) Duke Cancer Institute, Duke University; (6) Vanderbilt University Medical Center; (7) MD ANDERSON CANCER CENTER, Houston, TX, United States; (8) University of Chicago Medicine, Chicago, IL, United States; (9) Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States; (10) University of Pennsylvania; (11) Georgetown University; (12) University of North Carolina, Chapel Hill, NC, United States; (13) Baylor College of Medicine; (14) Indiana University; (15) University of Alabama at Birmingham/O’Neal Comprehensive Cancer Center, Birmingham, AL, United States; (16) Fred Hutchinson Cancer Center, Seattle, WA, United States; (17) Montefiore Medical Center; (18) Brigham and Women's

(1) Fondazione IRCCS Istituto Nazionale dei Tumori, Italy; (2) Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori; (3) IEO - European Institute of Oncology; (4) Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy; (5) Fondazione IRCCS Istituto Nazionale dei Tumori, Italy; (6) University of Milan; (7) University of Milan; IEO - European Institute of Oncology, Spain; (8) University of Milan; IFOM, the AIRC Institute of Molecular Oncology ETS, Spain; (9) University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Spain; (10) Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Lombardia, Italy.